Sulforaphane Inhibits Adhesion and Migration of Cisplatin- and Gemcitabine-Resistant Bladder Cancer Cells In Vitro

被引:2
|
作者
Xie, Hui [1 ,2 ]
Rutz, Jochen [1 ]
Maxeiner, Sebastian [1 ]
Grein, Timothy [2 ]
Thomas, Anita [1 ]
Juengel, Eva [1 ]
Chun, Felix K. -H. [2 ]
Cinatl, Jindrich [3 ]
Haferkamp, Axel [1 ]
Tsaur, Igor [1 ]
Blaheta, Roman A. [1 ,2 ]
机构
[1] Univ Med Ctr Mainz, Dept Urol & Pediat Urol, D-55131 Mainz, Germany
[2] Goethe Univ, Dept Urol, D-60590 Frankfurt, Germany
[3] Goethe Univ, Inst Med Virol, D-60596 Frankfurt, Germany
关键词
sulforaphane; bladder cancer; drug-resistance; chemotaxis; integrins; cadherins; BETA-CATENIN; EXPRESSION; SENSITIVITY;
D O I
10.3390/nu16050623
中图分类号
R15 [营养卫生、食品卫生]; TS201 [基础科学];
学科分类号
100403 ;
摘要
Only 20% of patients with muscle-invasive bladder carcinoma respond to cisplatin-based chemotherapy. Since the natural phytochemical sulforaphane (SFN) exhibits antitumor properties, its influence on the adhesive and migratory properties of cisplatin- and gemcitabine-sensitive and cisplatin- and gemcitabine-resistant RT4, RT112, T24, and TCCSUP bladder cancer cells was evaluated. Mechanisms behind the SFN influence were explored by assessing levels of the integrin adhesion receptors beta 1 (total and activated) and beta 4 and their functional relevance. To evaluate cell differentiation processes, E- and N-cadherin, vimentin and cytokeratin (CK) 8/18 expression were examined. SFN down-regulated bladder cancer cell adhesion with cell line and resistance-specific differences. Different responses to SFN were reflected in integrin expression that depended on the cell line and presence of resistance. Chemotactic movement of RT112, T24, and TCCSUP (RT4 did not migrate) was markedly blocked by SFN in both chemo-sensitive and chemo-resistant cells. Integrin-blocking studies indicated beta 1 and beta 4 as chemotaxis regulators. N-cadherin was diminished by SFN, particularly in sensitive and resistant T24 and RT112 cells, whereas E-cadherin was increased in RT112 cells (not detectable in RT4 and TCCSup cells). Alterations in vimentin and CK8/18 were also apparent, though not the same in all cell lines. SFN exposure resulted in translocation of E-cadherin (RT112), N-cadherin (RT112, T24), and vimentin (T24). SFN down-regulated adhesion and migration in chemo-sensitive and chemo-resistant bladder cancer cells by acting on integrin beta 1 and beta 4 expression and inducing the mesenchymal-epithelial translocation of cadherins and vimentin. SFN does, therefore, possess potential to improve bladder cancer therapy.
引用
收藏
页数:14
相关论文
共 50 条
  • [21] Mass Spectrometry-Based Metabolic Profiling of Gemcitabine-Sensitive and Gemcitabine-Resistant Pancreatic Cancer Cells
    Fujimura, Yoshinori
    Ikenaga, Naoki
    Ohuchida, Kenoki
    Setoyama, Daiki
    Irie, Miho
    Miura, Daisuke
    Wariishi, Hiroyuki
    Murata, Masaharu
    Mizumoto, Kazuhiro
    Hashizume, Makoto
    Tanaka, Masao
    PANCREAS, 2014, 43 (02) : 311 - 318
  • [22] Identifying microRNA-mRNA regulatory network in gemcitabine-resistant cells derived from human pancreatic cancer cells
    Shen, Yehua
    Pan, Yan
    Xu, Litao
    Chen, Lianyu
    Liu, Luming
    Chen, Hao
    Chen, Zhen
    Meng, Zhiqiang
    TUMOR BIOLOGY, 2015, 36 (06) : 4525 - 4534
  • [23] Gemcitabine-Loaded Albumin Nanoparticle Exerts An Antitumor Effect on Gemcitabine-Resistant Pancreatic Cancer Cells Induced by MDR1 and MRP1 Overexpression in Vitro
    Kong, Lei
    Du, Jiali
    Gu, Jichun
    Deng, Junyuan
    Guo, Yujie
    Tao, Baian
    Jin, Chen
    Fu, Deliang
    Li, Ji
    FRONTIERS IN SURGERY, 2022, 9
  • [24] A G-quadruplex-binding compound shows potent activity in human gemcitabine-resistant pancreatic cancer cells
    Ahmed, Ahmed Abdullah
    Marchetti, Chiara
    Ohnmacht, Stephan A.
    Neidle, Stephen
    SCIENTIFIC REPORTS, 2020, 10 (01)
  • [25] Characterization and treatment of gemcitabine- and cisplatin-resistant bladder cancer cells with a pan-RAS inhibitor
    Yoshino, Hirofumi
    Yokoyama, Seiya
    Tamai, Motoki
    Okamura, Shunsuke
    Iizasa, Sayaka
    Sakaguchi, Takashi
    Osako, Yoichi
    Inoguchi, Satoru
    Matsushita, Ryosuke
    Yamada, Yasutoshi
    Nakagawa, Masayuki
    Tatarano, Shuichi
    Tanimoto, Akihide
    Enokida, Hideki
    FEBS OPEN BIO, 2023, 13 (06): : 1056 - 1066
  • [26] Exosomes derived from cancer stem cells of gemcitabine-resistant pancreatic cancer cells enhance drug resistance by delivering miR-210
    Yang, Zhiyong
    Zhao, Ning
    Cui, Jing
    Wu, Heshui
    Xiong, Jiongxin
    Peng, Tao
    CELLULAR ONCOLOGY, 2020, 43 (01) : 123 - 136
  • [27] Digoxin sensitizes gemcitabine-resistant pancreatic cancer cells to gemcitabine via inhibiting Nrf2 signaling pathway
    Zhou, Yunjiang
    Zhou, Yang
    Yang, Mengdi
    Wang, Keke
    Liu, Yisi
    Zhang, Mingda
    Yang, Yunjia
    Jin, Chenyu
    Wang, Rui
    Hu, Rong
    REDOX BIOLOGY, 2019, 22
  • [28] The disintegrin tzabcanin inhibits adhesion and migration in melanoma and lung cancer cells
    Saviola, Anthony J.
    Burns, Patrick D.
    Mukherjee, Ashis K.
    Mackessy, Stephen P.
    INTERNATIONAL JOURNAL OF BIOLOGICAL MACROMOLECULES, 2016, 88 : 457 - 464
  • [29] Down-regulation of microRNA-20a in gemcitabine-resistant pancreatic cancer in in vitro microRNA integrative analysis
    Li, Guo-Ping
    Gong, Gao-Quan
    Chen, Yi
    Li, Chang-Yu
    Wang, Xiao-Lin
    INTERNATIONAL JOURNAL OF CLINICAL AND EXPERIMENTAL PATHOLOGY, 2017, 10 (05): : 5694 - 5702
  • [30] Down-regulation of miR-223 reverses epithelial-mesenchymal transition in gemcitabine-resistant pancreatic cancer cells
    Ma, Jia
    Fang, Binbin
    Zeng, Fanpeng
    Ma, Cong
    Pang, Haijie
    Cheng, Long
    Shi, Ying
    Wang, Hui
    Yin, Bin
    Xia, Jun
    Wang, Zhiwei
    ONCOTARGET, 2015, 6 (03) : 1740 - 1749